|
Fig. 7 Representative Western blot showing the expression level analysis of WT, S766F mutant SERCA1 proteins after incubation with proteasome inhibitor MG132 and CFTR correctors at different concentrations. HeLa cells transfected with WT and S766F SERCA1 cDNAs were treated with the proteasome inhibitor MG132 (10 µM) or its vehicle DMSO (0.1%) and S766F mutants were also exposed to different concentrations of C17 and C4 CFTR correctors. An equal quantity of protein from total cell lysates was separated by SDS-PAGE and subjected to immunoblot analysis with antibodies specific to SERCA1 and 42 kDa beta-actin, used as loading control.